Clinical trials
Arthritis, Rheumatoid trials in Switzerland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
71 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 5 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 7 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 52 |
| Active, not recruiting | 7 |
| Terminated | 5 |
| Unknown status | 3 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 11 |
| Bristol-Myers Squibb | 7 |
| Zimmer Biomet | 7 |
| AbbVie | 5 |
| Eli Lilly and Company | 4 |
| University of Zurich | 4 |
| Novartis | 3 |
| AstraZeneca | 2 |
| Rüdiger B. Müller | 2 |
| UCB BIOSCIENCES, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis, Rheumatoid | 71 |
| Osteoarthritis | 9 |
| Arthritis | 5 |
| Osteonecrosis | 5 |
| Spondylitis, Ankylosing | 5 |
| Arthritis, Psoriatic | 4 |
| Crohn Disease | 4 |
| Joint Diseases | 4 |
| Musculoskeletal Diseases | 4 |
| Axial Spondyloarthritis | 3 |
Trials
Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.